Precision Biosciences (DTIL) Non-Current Debt (2021 - 2026)
Precision Biosciences (DTIL) posted quarterly Non-Current Debt of $22.4 million for Q1 2026, little changed year-over-year from $22.3 million in Q1 2025, and little changed quarter-over-quarter from $22.4 million in Q4 2025.
Precision Biosciences (DTIL) Non-Current Debt (2021 - 2026) Analysis & Trends
Precision Biosciences (DTIL) has reported Non-Current Debt for 6 consecutive years, with $22.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Non-Current Debt changed 0.37% year-over-year to $22.4 million; the TTM figure through Mar 2026 stood at $22.4 million (changed 0.37% YoY), while the FY2025 annual figure was $22.4 million, changed 0.37% from the prior year.
- Non-Current Debt held at $22.4 million in Q1 2026 per DTIL's latest filing, from $22.4 million in the prior quarter.
- Across five years, Non-Current Debt topped out at $22.4 million in Q1 2026 and bottomed at $2.5 million in Q1 2022.
- Historically, Non-Current Debt has averaged $20.6 million across 5 years, with a median of $22.3 million in 2024.
- Annual changes were most pronounced in 2023 — Non-Current Debt jumped 797.26% — and 2026, when it grew 0.37%.
- Precision Biosciences' Non-Current Debt stood at $22.2 million in 2022, then rose by 0.21% to $22.3 million in 2023, then climbed by 0.23% to $22.3 million in 2024, then increased by 0.37% to $22.4 million in 2025, then increased by 0.07% to $22.4 million in 2026.
- Business Quant data shows DTIL's Non-Current Debt at $22.4 million in Q1 2026, $22.4 million in Q4 2025, and $22.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.20 Bn | 131.35 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 86.09 Bn | 78.10 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 65.25 Bn | 60.07 Bn | 1.37 Bn | - |
| 4 | Moderna | 59.04 Bn | 53.90 Bn | 52.00 Mn | 591.00 Mn |
| 5 | BeOne Medicines | 42.04 Bn | 36.94 Bn | 1.53 Bn | 882.16 Mn |
| 6 | Alnylam Pharmaceuticals | 31.61 Bn | 28.30 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.04 Bn | 9.65 Bn | 668.28 Mn | 360.97 Mn |
| 8 | Insmed | 27.50 Bn | 26.33 Bn | 358.27 Mn | 546.77 Mn |
| 9 | Royalty Pharma | 27.34 Bn | 26.50 Bn | - | 8.96 Bn |
| 10 | Precision Biosciences | 224.82 Mn | 137.27 Mn | - | 22.42 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 22.42 Mn |
| Mar 31, 2026 | 22.42 Mn |
| Dec 31, 2025 | 22.40 Mn |
| Sep 30, 2025 | 22.37 Mn |
| Jun 30, 2025 | 22.35 Mn |
| Mar 31, 2025 | 22.34 Mn |
| Dec 31, 2024 | 22.32 Mn |
| Sep 30, 2024 | 22.28 Mn |
| Mar 31, 2023 | 22.27 Mn |
| Dec 31, 2022 | 22.22 Mn |
| Sep 30, 2022 | 22.17 Mn |
| Jun 30, 2022 | 22.12 Mn |
| Mar 31, 2022 | 2.48 Mn |
| Dec 31, 2021 | 2.48 Mn |